Magnesium Citrate

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the relief of occasional constipation (irregularity). It generally produces a bowel movement within 1/2 to 6 hours of administration.

There are no known teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Shake the product well before use. Each dose should be taken with a full glass (8 ounces) of liquid. The medication may be administered as a single daily dose or divided into multiple doses throughout the day.

For adults and children aged 12 years and older, the recommended dosage is between 6.5 to 10 fluid ounces, with a maximum limit of 10 fluid ounces within a 24-hour period.

For children aged 6 to under 12 years, the dosage is 7 fluid ounces, with a maximum of 7 fluid ounces in a 24-hour period.

For children aged 2 to under 6 years, the dosage is 2 to 3 fluid ounces within a 24-hour period, with a maximum limit of 3 fluid ounces in that timeframe.

For children under 2 years of age, it is advised to consult a physician for appropriate dosing recommendations.

Contraindications

Use of this product is contraindicated in patients experiencing rectal bleeding or failure to have a bowel movement after use, as these may indicate a serious underlying condition.

Additionally, caution is advised for individuals with kidney disease, those on a magnesium-restricted diet, or those presenting with abdominal pain, nausea, or vomiting. Patients who have noticed a sudden change in bowel habits persisting for more than two weeks or who have used a laxative for longer than one week should also consult a healthcare professional prior to use.

Furthermore, it is recommended to seek advice from a doctor or pharmacist if the patient is currently taking any other medications, as this product should be administered at least two hours before or after other drugs to prevent potential interactions that may affect drug efficacy.

Warnings and Precautions

Healthcare professionals should exercise caution when recommending this product, particularly in patients with specific health conditions. It is imperative to consult a physician prior to use in individuals with the following conditions:

• Kidney Disease: Patients with compromised renal function may require special consideration due to potential alterations in drug metabolism and excretion.

• Magnesium Restricted Diet: Those adhering to a diet that limits magnesium intake should seek medical advice, as this product may contain magnesium.

• Gastrointestinal Symptoms: Patients experiencing abdominal pain, nausea, or vomiting should be evaluated before using this product.

• Changes in Bowel Habits: A sudden change in bowel habits persisting for two weeks warrants medical consultation prior to use.

• Prolonged Laxative Use: Individuals who have been using a laxative for more than one week should consult a healthcare provider before continuing treatment.

Additionally, it is advisable for patients to inform their healthcare provider or pharmacist if they are taking any other medications. This product should be administered at least two hours before or after other drugs, as laxatives may influence the efficacy of concurrent medications.

In the event of an overdose, immediate medical assistance should be sought, or the Poison Control Center can be contacted at 1-800-222-1222.

Patients should discontinue use and consult a physician if they experience rectal bleeding or fail to have a bowel movement after using the product, as these symptoms may indicate a serious underlying condition.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this product. Serious adverse reactions may include rectal bleeding or failure to have a bowel movement after use, which could indicate a serious underlying condition. In such cases, patients are advised to stop use immediately and consult a healthcare professional.

Before using this product, patients should seek medical advice if they have any of the following conditions: kidney disease, a magnesium-restricted diet, abdominal pain, nausea, or vomiting. Additionally, a sudden change in bowel habits that persists for more than two weeks or the prolonged use of a laxative for more than one week warrants consultation with a healthcare provider.

Patients are also encouraged to discuss their current medications with a doctor or pharmacist prior to use, as this product may interact with other drugs. It is recommended that this product be taken at least two hours before or after the administration of other medications to minimize potential interactions.

Drug Interactions

Laxatives, particularly magnesium citrate, may influence the efficacy of concurrent medications. It is recommended that this product be administered at least 2 hours before or after the intake of other drugs to minimize potential interactions.

Currently, there is no available information regarding other drug interactions or interactions with laboratory tests. Therefore, healthcare professionals should remain vigilant and monitor for any unexpected effects when magnesium citrate is used alongside other medications.

Packaging & NDC

Below are the non-prescription pack sizes of Magnesium Citrate (magnesium citrate oral solution - lemon). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 12 years and older may receive a dosage of 6.5 to 10 fl oz, with a maximum limit of 10 fl oz in a 24-hour period. For children aged 6 to under 12 years, the recommended dosage is 7 fl oz, not to exceed 7 fl oz in 24 hours. In children aged 2 to under 6 years, the dosage is 2 to 3 fl oz, with a maximum of 3 fl oz in 24 hours. For infants and children under 2 years of age, it is advised to consult a doctor before administration.

Geriatric Use

Elderly patients should exercise caution when using this medication, particularly those aged 65 and older. It is essential for geriatric patients to consult a healthcare provider prior to use if they have a history of kidney disease, as renal function may be compromised in this population, potentially affecting drug metabolism and excretion.

Additionally, patients on a magnesium-restricted diet should seek medical advice before initiating treatment, as the formulation may contain magnesium, which could exacerbate their condition. Geriatric patients experiencing abdominal pain, nausea, or vomiting should also consult a healthcare professional before use, as these symptoms may indicate underlying health issues that require further evaluation.

Furthermore, elderly patients who notice a sudden change in bowel habits persisting for more than two weeks should seek medical advice prior to using this medication. It is also important for those who have been using a laxative for longer than one week to consult a healthcare provider, as prolonged use may lead to dependency or other complications.

Patients should discontinue use and contact a healthcare professional if they experience rectal bleeding or fail to have a bowel movement after use, as these symptoms could signify a serious medical condition requiring immediate attention. Careful monitoring and appropriate dose modifications may be necessary to ensure the safety and efficacy of treatment in geriatric patients.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Renal impairment may necessitate dosage adjustments for patients with reduced kidney function. It is essential for healthcare professionals to monitor renal function regularly in these patients. Dosage adjustments should be based on creatinine clearance levels, ensuring that appropriate modifications are made to optimize therapeutic outcomes. Special consideration should be given to patients with severe renal impairment, as they may require more stringent management. Renal function tests are recommended prior to initiating therapy and should be conducted periodically thereafter to assess any changes in renal status.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, which may include airway management, intravenous fluids, and monitoring of vital parameters.

If specific antidotes or treatments are available for the substance involved, they should be administered according to established protocols. Consultation with a poison control center or toxicology expert may also be warranted to guide management decisions.

It is crucial to document all findings and interventions in the patient's medical record and to report any adverse events to the appropriate regulatory authorities as required.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. In the event of an overdose, patients should be instructed to seek medical help immediately or contact a Poison Control Center at 1-800-222-1222.

Patients should be informed to discontinue use and consult a doctor if they experience rectal bleeding or fail to have a bowel movement after using the product, as these symptoms may indicate a serious condition.

Before initiating treatment, healthcare providers should encourage patients to consult with a doctor if they have any of the following conditions: kidney disease, a magnesium-restricted diet, abdominal pain, nausea, or vomiting. Additionally, patients should be advised to seek medical advice if they notice a sudden change in bowel habits that persists for more than two weeks or if they have been using a laxative for longer than one week.

Furthermore, patients should be reminded to consult with a doctor or pharmacist before using this product if they are currently taking any other medications. It is important to instruct patients to take this laxative at least two hours before or after taking other drugs, as laxatives may influence the effectiveness of other medications.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at temperatures ranging from 46° to 86°F (8° to 30°C) to maintain its efficacy and safety. Proper storage conditions must be adhered to, ensuring that the product is kept within the specified temperature range to prevent degradation.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Magnesium Citrate, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)